Biotanika launches a randomized, blinded and placebo-controlled clinical trial evaluating multi-herb formulations in the treatment of arthrosis in dogs

    QUEBEC, Sept. 17 /CNW Telbec/ - Biotanika Inc. ("Biotanika") today
announces that it has launched earlier this year a randomized, blinded and
placebo-controlled trial evaluating its multi-herb formulations in the
treatment of arthrosis in dogs.
    Arthrosis is the most common joint disease affecting dogs. An estimated
20% of the canine population in North America suffer from arthrosis. As pain
related to arthrosis is often alleviated with non-steroidal anti-inflammatory
drugs that are known for their numerous adverse events, products to treat
canine arthrosis that are safe and effective are clearly needed.
    Biotanika awarded a research contract to Dr. Eric Troncy, DV, MSc, PhD,
DUn, Université de Montréal (UdeM), Faculty of Veterinary Medicine, for the
evaluation of its multi-herb formulations in dogs with arthrosis. According to
Dr. Chamberland, Vice-President Clinical and Regulatory Affairs at Biotanika,
"many natural health products are marketed without animal data or based on
trials performed in humans". He added that "this study is part of Biotanika's
commitment to the development and commercialization of safe and effective
natural health products for animals".
    Dr. Eric Troncy, DV, MSc, PhD, DUn, is Head of the Research Group on
Animal Pharmacology in Quebec (GREPAQ). He is an internationally recognized
member of the scientific community on animal pain evaluation and management.
Laureate of the Faculty of Medicine Claude-Bernard in Lyon (France), Ph.D. in
biomedical sciences of UdeM, University Doctorate in
pharmacology-pharmacochemistry of Université Louis Pasteur of Strasbourg
(France), he was nominated veterinarian of the year in France in 2001, for his
actions toward small animal pain. He is the author of more than 40 research
publications. He is also a convincing and appreciated speaker and a motivating
teacher. His studies have brought him several national or international prizes
and awards. Associate Professor in pharmacology at the UdeM, Faculty of
Veterinary Medicine, his actual area of research are the metrology of animal
pain, in acute and chronic conditions (mainly osteoarthritis), and the
relationship between pain assessment and genomic / proteomic modifications.
    This clinical trial is performed under randomized and blinded conditions
and will evaluate the safety and efficacy of multi-herb formulations versus a
placebo-control. Dogs are currently being recruited and enrolled to constitute
two groups, one placebo-control, and one receiving the multi-herb formulations
every day. Each dog will undergo serial veterinary clinical and paraclinical
(haematology, coagulation, biochemistry and X-rays) examinations, as well as
force plate evaluations to quantify ground reaction forces. In addition, some
of the dogs will continuously be monitored for the intensity and the
occurrence of locomotor activity using telemetric accelerometer chips.
Dr. Troncy and his team have developed methods to adequately evaluate the
efficacy of products for canine arthrosis. According to Dr. Troncy, "force
plate and telemetric accelerometry are validated methods to provide data on
the effectiveness of products to improve gait in dogs affected with arthrosis.
The assessment of the pain relief is complex in animals and that improvement
in gait is a good indicator of arthrosis-related pain / disability level, and
subsequent animal welfare and quality of life". "The research unit on dog
arthrosis of the UdeM, Faculty of Veterinary Medicine at St-Hyacinthe (QC) was
a precursor in animal gait analysis ten years ago" quoted Mr. Maxim Moreau,
Project manager. "Cited for the quality of its work in evidence-based medicine
systematic reviews, this group is recognized for the high level of care
provided to animals and owners, its rigorous selection criteria and the
non-invasive, innovative, precise, and validated methods of arthrosis-related
canine pain assessment ... and the dog owners in Quebec are responding
favourably to their solicitation for clinical trials".
    Benoit Côte, President and CEO of Biotanika commented that "there are
many natural health products on the market and a rigorous assessment of the
safety and efficacy of these products is required".

    About Biotanika

    Biotanika is a Canadian company headquartered in Quebec City. It operates
two divisions:

           Biotanika Health (human health):

           Biotanika Health develops and markets natural health products
           containing ingredients whose efficacy has been scientifically
           proven. These products provide an alternative to prescription
           drugs for people suffering from pathologies that affect their
           quality of life.

           Biotanika Animal (companion animals)

           Biotanika Animal develops and commercializes pet food supplements
           combining various ingredients from botanical source. Our products
           are tested by clinicians to demonstrate their ability to promote
           companion animals' health.

    Biotanika experienced management team has an extensive background in the
pharmaceutical industry and is specialized in preclinical, clinical and
regulatory development of drugs and natural health products, as well as in
marketing and retailing.

For further information:

For further information: Benoit Côte, President and CEO, (418) 653-3423
ext. 701,,; Source:
Biotanika Health Inc.

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890